Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 04/10/2025

Tocilizumab Products

Actemra® (tocilizumab)
Avtozma® (tocilizumab-anoh)
Tofidence™ (tocilizumab-bavi)
Tyenne™ (tocilizumab-aazg)

HCPCS: Actemra: J3262; Avtozma: J3590; Tofidence: Q5133; Tyenne: Q5135

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

A. Coverage of the requested drug is provided when all the following are met:
   a. FDA approved indications
   b. FDA approved age
   c. Diagnosis of rheumatoid arthritis (RA):
      i. Trial and failure of at least 3 months of one disease-modifying anti-rheumatic agent (DMARD) unless contraindicated or not tolerated. Examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine
   d. Diagnosis of polyarticular juvenile idiopathic arthritis (pJIA)
      i. Trial and failure of at least 3 months of one DMARD unless contraindicated or not tolerated. Examples include methotrexate and leflunomide
   e. Diagnosis of Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD)
      i. Trial and treatment failure with one of the following: glucocorticoids or NSAIDs
   f. Diagnosis of cytokine release syndrome (CRS)
      i. Prescribed by or in consultation with an oncologist
      ii. Severe or life-threatening CRS associated with chimeric antigen receptor (CAR)-T cell therapy
   g. Diagnosis of giant cell arteritis (GCA)
   h. Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
      i. Inadequate response to (as evidenced by disease progression - e.g. worsening of pulmonary function) or not a candidate for either mycophenolate mofetil OR cyclophosphamide
   i. The member will self-administer tocilizumab unless clinically unable to do so.
   j. Not to be used in combination with other biologics or other targeted DMARDs for the same indication
   k. Coverage will be provided for biosimilar products for FDA labeled indications of the innovator product when criteria are met

l. Trial and failure of the preferred products as specified in the BCBSM/BCN utilization management medical drug list and/or the BCBSM/BCN prior authorization and step therapy documents

B. Quantity Limitations, Authorization Period and Renewal Criteria
   a. Quantity Limits: Align with FDA recommended dosing
   b. Initial Authorization Period:
      i. RA, pJIA, sJIA, GCA, AOSD, SSc-ILD: One year at a time
      ii. CRS: 60 days
   c. Renewal Criteria:
      i. RA, pJIA, sJIA, GCA, AOSD, SSc-ILD: Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit
      ii. CRS: Not applicable as no further authorization will be provided

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at http://www.cms.hhs.gov/. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Tocilizumab is an interleukin-6 inhibitor (IL-6i) available as the innovator product Actemra and its biosimilars Avtozma, Tofidence, and Tyenne.
  - Actemra is indicated for RA, GCA, pJIA, sJIA, CRS, SSc-ILD, and COVID-19. It is available for both subcutaneous (SC) and intravenous (IV) administration. For CRS and COVID-19, only the IV formulation is approved for use whereas only the SC formulation is approved for SSc-ILD. Either Actemra formulation may be used for all other indications.
  - In contrast to the innovator product, Avtozma, Tofidence, and Tyenne are approved for RA, pJIA, sJIA, GCA and COVID-19. Tyenne also carries an additional indication for CRS. Tofidence is only available in an IV formulation, whereas Avtozma and Tyenne are available in IV and SC formulations.
- Tocilizumab has not been studied in combination with other biologic disease-modifying agents such as tumor necrosis factor inhibitors, interleukin receptor antagonists, anti-CD20 monoclonal antibodies, and selective co-stimulation modulators due to an increased risk of infection and increased immunosuppression. As such, use of tocilizumab products in combination with other biologic agents is not recommended.
- Rheumatoid Arthritis
  - The 2021 American College of Rheumatology (ACR) Guidelines for the Treatment of Rheumatoid Arthritis (RA) established recommendations for the care of adult RA patients. The guidelines state that treatment decisions should follow a shared decision-making process and should be reevaluated within a minimum of 3 months based on the efficacy and tolerability of the DMARD(s) chosen.
  - For the initial treatment of symptomatic RA, the guidelines strongly recommend the use of conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy in those who are DMARD-naive. csDMARD monotherapy is a less costly first line treatment option with an extensive safety record accompanied by well-documented clinical efficacy and a large body of clinical experience and familiarity among prescribers. csDMARDs in the guidelines refer to methotrexate (MTX), hydroxychloroquine, leflunomide (LEF), and sulfasalazine. Azathioprine, cyclosporine, minocycline, and gold were not included

due to their infrequent use in RA and lack of new data since the prior guidelines were published. Oral MTX is recommended as the preferred initial DMARD for patients with moderate-to-high disease activity, and hydroxychloroquine is recommended as the preferred initial DMARD for patients with low disease activity.

- If disease activity remains moderate or high despite optimal dosing of methotrexate monotherapy, the use of dual therapy with methotrexate plus biologic DMARD (bDMARD; etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, abatacept, tocilizumab, sarilumab, rituximab) or targeted synthetic DMARD (tsDMARD; tofacitinib, baricitinib, upadacitinib) therapy is conditionally recommended over the use of triple therapy (i.e., addition of sulfasalazine and hydroxychloroquine). The guidelines do not inform preference of bDMARD over tsDMARD therapy (or vice-versa) for use in combination with methotrexate. No one agent has been shown to be superior to another. The guidelines do acknowledge the emergence of safety signals for the JAK inhibitor class (tsDMARD), and state that further modification of this recommendation may be necessary as additional data are published.

- A treat-to-target approach is conditionally recommended over usual care for patients who have had an inadequate response to bDMARDs or tsDMARDs. Treat-to-target refers to a systematic approach involving frequent monitoring of disease activity using validated instruments and modification of treatment to minimize disease activity with the goal of reaching a pre-defined target (low disease activity or remission).

- Tocilizumab is indicated for treating adult patients with moderately to severely active RA who have had an inadequate response to one or more DMARDs. Tocilizumab may be used as monotherapy or concomitantly with other non-biologic DMARDs as an IV infusion or as a subcutaneous injection for the treatment of RA.

- Polyarticular Juvenile Idiopathic Arthritis

  - Juvenile idiopathic arthritis (JIA) defines a collection of inflammatory arthritides of unknown etiology. JIA onset is prior to 16 years of age with a minimum duration of 6 weeks and other potential causes of synovitis are excluded. JIA can be subdivided into pJIA and sJIA.

  - pJIA is defined by the presence of more than 4 affected joints in the first 6 months of illness and comprises 20-30% of children with JIA. Therapy is directed toward treating the underlying inflammation and preventing JIA-associated complications and adverse effects of its treatment.

  - The 2019 American College of Rheumatology/Arthritis Foundation (ACR/AF) guideline for the treatment of JIA strongly recommends initial therapy for pJIA with a DMARD such as MTX or LEF. MTX is conditionally recommended over LEF as it has a greater volume of data supporting its effectiveness compared to LEF and can be administered subcutaneously (recommended) or orally. The guidelines consider an adequate trial of a DMARD to be 3 months.

  - If moderate or high disease activity persists despite adequate DMARD use, the ACR/AF guidelines recommend biologic agents either in combination with a DMARD or as monotherapy in certain situations. Biologic agents FDA approved for pJIA in patients 2 years of age and older include Humira® (adalimumab), Enbrel® (etanercept), tocilizumab, Orencia® (abatacept), Simponi Aria® (golimumab), Xeljanz® (tofacitinib), Xeljanz (tofacitinib) oral solution, and Cimzia® (certolizumab pegol).

    - Of note, biologic therapy may be an appropriate initial therapy in pJIA patients with risk factors and involvement of high-risk joints, high disease activity, and/or for those judged to be at high risk of disabling joint damage.

  - There is the most experience with tumor necrosis factor inhibitors (TNFi; Humira, Enbrel, Simponi Aria) as initial biologic therapy; however, the preferred class of initial biologic is not specified in the guideline

recommendations due to a lack of comparative data and the consideration that non-TNFi biologics may be preferred in certain patient-specific scenarios. If a TNFi is started as the initial biologic, switching to a non-TNFi (tocilizumab or Orencia) is recommended over switching to a second TNFi. An exception to this is for those who had a good initial response to the first TNFi.

- Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease

    - sJIA is a rare and distinct subset of JIA. It accounts for 4-15% of JIA and is defined as arthritis in > 1 joint for at least 6 weeks duration in a child age < 16 years with or preceded by a fever of at least 2 weeks duration that is documented to be daily for at least 3 days and accompanied by one or more of the following: evanescent erythematous rash, generalized lymphadenopathy, hepatomegaly or splenomegaly, and serositis. This condition can occur in adulthood with similar features and is referred to as AOSD when diagnosed in patients 16 years of age and older.

    - AOSD and sJIA may also be complicated by macrophage activation syndrome (MAS), a secondary hemophagocytic syndrome that can be life-threatening and requires urgent recognition and treatment. MAS presents with fevers, high ferritin levels, cytopenias, elevated liver enzyme, low fibrinogen levels, and high triglyceride levels. Regardless of MAS presence at presentation, careful monitoring is necessary as MAS can occur at any point during the disease course.

    - The inflammatory process underlying sJIA and AOSD appears to be distinct from other categories of JIA, with interleukin (IL)-1 and IL-6 playing a central role. The goal of therapy focuses on prompt control of active inflammation and symptoms and prevention of disease- and or treatment-related morbidities like growth disturbances, joint damage and functional limitations.

    - Treatment recommendations vary depending on the presence of MAS. The 2021 ACR guideline for pharmacologic management of oligoarthritis, TMJ arthritis, and sJIA in children recommend the following for the treatment of sJIA:

        - Classes of pharmacologic interventions addressed in the recommendations include:

            - Any NSAIDs at therapeutic dosing

            - Traditional DMARDs (i.e., methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, calcineurin inhibitors (cyclosporin A, tacrolimus))

            - Biologics (i.e., tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol), abatacept, IL inhibitors (tocilizumab, anakinra, canakinumab))

            - Glucocorticoids, including any oral or intravenous agent, or intraarticular triamcinolone acetonide or triamcinolone hexacetonide.

        - In the presence of MAS, an IL-1 or IL-6 inhibitor (no preferred agent) and/or systemic glucocorticoids are recommended for initial treatment. If residual arthritis is present, a traditional DMARD may be added or treatment can be switched to a different biologic agent (no preferred agent).

        - In sJIA without MAS, the guidelines recommend monotherapy with an IL-1 or IL-6 inhibitor (no preferred agent) and/or a brief trial of scheduled NSAIDs. The guidelines do not provide a recommended duration of initial use for NSAIDs. Traditional DMARDs are strongly recommended

against as initial monotherapy as they are minimally effective at controlling systemic features of sJIA alone. Glucocorticoids are also conditionally recommended against as initial monotherapy; however, they may be used to help control systemic and joint manifestations of sJIA until an IL-1 or IL-6 inhibitor can be started. If a patient experiences an incomplete response or intolerance to first-line treatment, switching to an alternative IL-1 or IL-6 inhibitor is recommended (no preferred agent).

- Regardless of the presence of MAS, if a patient responds to initial treatment but residual arthritis is present, a traditional DMARD or switch to a different biologic (no preferred agent) is recommended.

- Ultimately, treatment is continued and the patient monitored until the sJIA becomes inactive, at which point it is recommended that the patient taper and stop biologics and/or glucocorticoids.

- Tocilizumab and Ilaris® (canakinumab; IL-1 inhibitor) are FDA approved for the treatment of sJIA in patients 2 years of age and older, while Ilaris is the only drug approved for the treatment of AOSD. There are no guidelines for treating AOSD; however, literature recommends a similar treatment approach to sJIA. The use of tocilizumab in AOSD is supported by a small, randomized trial and several case reports and case series that have shown efficacy in patients with AOSD with both the intravenous and subcutaneous formulations. Tocilizumab's efficacy in patients with sJIA also serves as additional evidence to support its use in AOSD.

- Cytokine Release Syndrome

  - CRS is an acute systemic inflammatory syndrome that is characterized by fever with or without multiple organ dysfunction occurring in response to chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies and haploidentical allogeneic hematopoietic cell transplantation (HCT). The incidence of CRS varies based on the causative treatment and underlying malignancy. It most often occurs following targeted cellular immunotherapy for B cell acute lymphoblastic leukemia/lymphoma (ALL/LBL), non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), and is less common following immunotherapy with bispecific antibodies and in the treatment of solid tumors.

  - The systemic inflammatory reaction that occurs with CRS involves increased levels of inflammatory cytokines and activation of T lymphocytes, macrophages, and endothelial cells; IL-6 appears to have a central role in CRS pathophysiology. The resulting manifestation of the CRS inflammatory response includes fever, which may be accompanied by fatigue, headache, rash, diarrhea, arthralgia, and myalgia. Mild CRS may progress to a more severe form, which may include hypotension, hypoxia, and uncontrolled systemic inflammatory response with circulatory collapse, vascular leakage, peripheral and/or pulmonary edema, renal failure, cardiac dysfunction, and multiorgan system failure. Neurologic manifestations may also develop in severe CRS, including aphasia, altered level of consciousness, impaired cognitive skills, motor weakness, seizures, and cerebral edema.

  - Diagnosis is made by clinical presentation and the temporal relationship to the triggering immune therapy. CRS typically begins within 1-14 days after CAR-T cell therapy with resolution within a few days to 2-3 weeks post CAR-T infusion. CRS diagnosis requires a fever (≥38°C) at onset, with or without hypotension, hypoxia, and/or other end-organ dysfunction in the hours to days after treatment with immune therapy like CAR-T. Due to variability of laboratory findings in CRS, laboratory studies are not required for diagnosis though they may be beneficial for differential diagnosis.

  - The severity of CRS is graded differently based on the causative immune therapy; literature includes diverse grading scales as there are various grading scales proposed for CRS. CAR-T therapy grading proposed by

the American Society for Transplantation and Cellular Therapy (ASTCT) is based on the degree and type of interventions required for patient management.

- Grade 1: Temperature ≥38°C and no hypotension and no hypoxia (defined by a requirement for supplemental oxygen to correct an oxygen deficit vs. a specific level of oxygen saturation). Patients may have malaise, myalgias, or arthralgias, but the severity of these constitutional symptoms does not affect the grade of CRS

- Grade 2: Temperature ≥38°C plus hypotension that does not require vasopressors and/or hypoxia that requires low-flow nasal cannula (≤6 L/minute or blow-by oxygenation). See the notes below regarding aspects of the management of hypotension and hypoxia that may affect grading.

- Grade 3: Temperature ≥38°C plus hypotension that requires one vasopressor (with or without vasopressin) and/or hypoxia requiring high-flow nasal cannula (≥6 L/minute), facemask, non-rebreather mask, or Venturi mask that is not attributable to any other cause.

- Grade 4: Temperature ≥38°C plus hypotension that requires multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation and mechanical ventilation). Intubation for reasons other than hypoxia alone does not meet criteria for Grade 4 CRS.

- The National Comprehensive Cancer Network (NCCN) guidelines for management of immunotherapy-related toxicities (version 1.2022) recommends treatment with Actemra (tocilizumab) for patients with Grade 2, 3 or 4 CRS related to CAR-T cell therapies either as monotherapy or in conjunction with IV corticosteroids. NCCN recommends considering Actemra treatment for prolonged (> 3 days) Grade 1 CRS in patients with significant symptoms, comorbidities, and/or are elderly.

- Actemra is FDA approved for treating severe or life-threatening CRS due to CAR-T cell therapy in patients 2 years of age and older. If there is no improvement after the first dose, the dose may be repeated in 8 hours for a maximum of 3 doses in 24 hours and 4 doses total. The need for subsequent dosing must be assessed after each dose.

- CAR-T therapy is currently only administered as one dose per lifetime; it has not been studied in patients who received prior treatment with any CAR-T therapy or other genetically modified T-cell therapy. As such, the use of Actemra for CRS related to CAR-T is limited to a one-time treatment.

- The FDA REMS program regulates CAR-T cell products in the United States. REMS guidelines should be consulted for specific details of CRS management as guidelines for treating CRS associated with CAR-T cell therapy varies according to the specific product.

- Giant Cell Arteritis

  - GCA (also known as Horton disease, cranial arteritis, and temporal arteritis) is the most common systemic vasculitis in North America, affecting adults over 50 years of age with a peak incidence between ages 70 and 79. Symptoms and signs of GCA typically results from vascular inflammation of the small extracranial branches of the carotid arteries; however, the disease is systemic and may involve the aorta and large arteries, leading to aneurysms of the thoracic and abdominal aorta ischemic symptoms in the extremities, respectively.

  - Manifestations of GCA vary between patients and may be transient or fluctuating. Systemic symptoms are frequent and may include fever, fatigue and weight loss. Diagnosis of GCA should be considered in patients

over 50 years old complaining of or found to have one or more of the following symptoms, the significance of which is heightened if a patient has a current or prior diagnosis of polymyalgia rheumatica:

  - New headache
  - Abrupt onset of visual disturbances, in particular transient monocular visual loss
  - Jaw claudication
  - Unexplained fever or anemia
  - Elevated erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP)

- The most significant complication of GCA is vision loss, which most frequently arises from cranial arteritis, a major phenotype of GCA. Approximately 25-50% of untreated patients who present with vision loss in one eye will develop bilateral blindness, and once visual impairment due to GCA is established, it is rarely reversible. Another concern is subclinical involvement of the aorta and large arteries (large vessel GCA), which occurs frequently and may result in aortic aneurysm and dissection.

- The 2021 ACR/Vasculitis Foundation Guideline for GCA and Takayasu Arteritis recommends temporal artery biopsy as the gold standard for GCA diagnosis; scheduling of the biopsy, however, should not interfere with treatment initiation when there is a high likelihood of GCA as a delay can put patients at risk of significant complications, particularly vision loss. In patients with a negative biopsy but high GCA suspicion, the guideline conditionally recommends noninvasive vascular imaging of the large vessels with clinical assessment to aid in diagnosis. The diagnostic procedure of choice for suspected large vessel GCA is advanced imaging of the torso (i.e. CT, MRI, PET scan).

- High dose glucocorticoid treatment (typically prednisone for 2-4 weeks) followed by a slow oral glucocorticoid taper is typically the mainstay of therapy for GCA and should be instituted promptly if a diagnosis of GCA is strongly suspected, especially in the event of recent or threatened vision loss. The initiation of IV or oral glucocorticoids is determined based on the presence of visual symptoms/loss or critical cranial ischemia. Prompt glucocorticoid treatment reduces the risk of sight loss to less than 1% in patients with intact vision at time of treatment initiation. Glucocorticoid effectiveness in GCA is well established by decades of clinical experience, producing prompt improvement of signs and symptoms generally within 24 to 48 hours of treatment initiation.

- The 2021 guideline conditionally recommends the use of glucocorticoids combined with tocilizumab or other non-glucocorticoid immunosuppressants over oral glucocorticoids alone for patients with newly diagnosed GCA; however, the guideline ultimately defers to the treating physician and the patient's clinical condition, values, and preferences in making the decision to treat with glucocorticoid monotherapy or combination therapy. Once a patient is in clinical remission, the oral glucocorticoids can be tapered.

- Relapses may occur and are most common at prednisone doses less than 20 mg/day; these are treated with increases in the glucocorticoid dose appropriate to the relapse, and/or the addition of a nonglucocorticoid immunosuppressants like tocilizumab or methotrexate. The optimal duration of therapy for GCA is not well established given the variable presentation and duration of symptoms and may extend from one to multiple years. The 2021 guideline panel takes the position that the duration of therapy should be guided by the patient and emphasized minimizing the use of glucocorticoids as much as possible due to glucocorticoid toxicity; however, the panel recognized that longer-term use may be needed in select patients to avoid relapses and flares.

- Potential toxicities of glucocorticoids are of concern in patients of advanced age, with comorbid conditions (e.g., preexisting diabetes mellitus, osteoporosis, significant obesity), and utilizing glucocorticoid therapy for extended periods of time. The prevalence of significant glucocorticoid-related adverse events correlates with increased patient age and cumulative glucocorticoid dose. Based on the patient population affected by GCA and the prolonged exposure to glucocorticoids, early implementation of glucocorticoid-sparing agents like tocilizumab may be preferred to minimize toxicity risk.

- Tocilizumab is FDA approved for the treatment of GCA in adults based on safety and efficacy data from pivotal trials that evaluated tocilizumab for both new-onset and relapsing GCA. For the treatment of GCA, tocilizumab is recommended in combination with a tapering course of glucocorticoids; monotherapy with Actemra may be continued following glucocorticoid discontinuation.

- Systemic sclerosis-associated interstitial lung disease

  - SSc-ILD is a rare autoimmune disease affecting about 75,000 people in the U.S. It is characterized by thickening, hardening, and scarring of the skin and caused by the accumulation of excess collagen in the skin and internal organs, such as the heart, lungs, kidneys, and intestinal tract, leading to organ damage. An estimated 80% of patients have ILD due to the buildup of scar tissue and inflammation in the lungs. ILD is a progressive disease that can significantly impact lung function.

  - Mycophenolate and cyclophosphamide are considered standard of care as initial therapy as supported by numerous clinical trials and the European League Against Rheumatism (EULAR) guidelines for SSc (updated in 2017). Mycophenolate is often preferred in practice as it has comparable benefit to cyclophosphamide but has a better toxicity profile. Ofev® and more recently Actemra subcutaneous injection received FDA approval for this indication and are options for patients who are not candidates for mycophenolate or cyclophosphamide.

  - The approval of Actemra was based on the results of a Phase III, placebo-controlled trial. The trial did not meet its primary goal of a change on a standard skin fibrosis measurement called the modified Rodnan Skin Score (mRSS). However, based on a post hoc subgroup analysis, a benefit was apparent in patients with confirmed SSc-ILD. Analyses found that these Actemra-treated patients, relative to those on placebo, had a smaller decline in mean forced vital capacity (FVC).

- COVID-19

  - On December 21, 2022, Actemra was approved for the treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This approval is for adults aged 18 and older only. There is still an Emergency Use Authorization in place for use of Actemra for treatment of COVID-19 in hospitalized patients aged 2-17.

  - Actemra comes in 2 formulations: an IV infusion formulation and a subcutaneous injection formulation. The FDA approval for COVID-19 only pertains to the IV formulation as the medication should not be self-administered in the hospital. The recommended dosage of Actemra for adult patients with COVID-19 is 8 mg/kg administered via a 60-minute IV infusion.

  - The National Institutes of Health (NIH) COVID-19 Treatment Guidelines recommend oral Olumiant® (baricitinib) or IV Actemra in addition to dexamethasone in patients who are hospitalized requiring high-flow nasal cannula (HFNC) oxygen or noninvasive ventilation (NIV), or in patients who are hospitalized requiring ECMO or mechanical ventilation (MV).

- The primary outcome in the RECOVERY trial was 28-day mortality in those receiving Actemra compared to usual care alone. The rate ratio was 0.85; (95% CI 0.76-0.94; p=0.0028) demonstrating that Actemra was statistically significant in reducing 28-day mortality compared to usual care alone. Additionally, among patients who were not receiving invasive mechanical ventilation at baseline in the RECOVERY trial, patients on Actemra were less likely to reach the composite endpoint of invasive mechanical ventilation or death. The risk ratio was 0.84; (95% CI, 0.77-0.92; p <0.0001).

References:

1. Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; December 2022.
2. Avtozma [prescribing information]. Jersey City, NJ: Celltrion, Inc.; January 2025.
3. Cimzia (certolizumab pegol) [prescribing information]. Smyrna, GA: UCB, Inc. September 2019.
4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 02/21/2023.
5. Docken WP and Rosenbaum JT. Clinical manifestations of giant cell arteritis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.
6. Docken WP. Diagnosis of giant cell arteritis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.
7. Docken WP. Treatment of giant cell arteritis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.
8. Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation; March 2020.
9. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021 Jul; 73 (7):924-939.
10. Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie; March 2020.
11. Ilaris (canakinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; June 2020.
12. Inflectra (infliximab-dyyb) [prescribing information].New York, NY: Pfizer; June 2019.
13. Kevzara (sarilumab) [prescribing information]. Bridgewater, NJ: Sanofi0Aventis; April 2018.
14. Kineret (anakinra) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; June 2018.
15. Kowal-Bielecka O, Fransen J, Avouac J EUSTAR Coauthors, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases 2017;76:1327-1339.
16. Mandl L. Treatment of adult Still's disease. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.
17. Maz M, Chung SA, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guidelines for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774. Epub 2021 Jul 8. PMID: 34235884.
18. National Comprehensive Cancer Network Guidelines Version 1.2022. Management of Immunotherapy-Related Toxicities. Accessed on January 26, 2023
19. Olumiant (baricitinib) [prescribing information]. Indianapolis, IN: Eli Lilly; July 2020.
20. Onel KB, Horton db, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Tempomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022 Apr;74(4):553-569. doi: 10.1002/art.42037. Epub 2022 Mar 1.
21. Orencia (abatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; June 2020.
22. Porter DL and Maloney DG. Cytokine release syndrome (CRS). In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.
23. RECOVERY Collaborative Group. "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial." Lancet (London, England) vol. 397,10285 (2021): 1637-1645. doi:10.1016/S0140-6736(21)00676-0
24. Reihl Crnogaj M, Čubelić D, Babić A, Mayer M, Anić B. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review. Rheumatol Int. 2020 Aug;40(8):1317-1325. Doi: 10.1007/s00296-020-04622-4. Epub 2020 Jun 6.
25. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2020.
26. Renflexis (infliximab-abda) [prescribing information]. Whitehouse Station, NJ: Merc Sharp & Dohme Corp; February 2020.

27. Ringold et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of JIA. Arthritis Care and Research. Vol 71 No 6 Jun 2019.
28. Rinvoq (upadacitinib) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.
29. Rituxan (rituximab) [prescribing information]. South San Francisco, CA: Genentech Inc; August 2020.
30. Simponi (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; September 2019.
31. Simponi Aria (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; September 2019.
32. Tofidence (prescribing information). Cambridge, MA: Biogen; December 2024.
33. Tyenne [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; February 2025.
34. Vandemergel X, Vandergheynst F. Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease. Acta Medica (Hradec Kralove). 2016;59(1):22-5. Doi: 10.14712/18059694.2016.51.
35. Varga J, Montesi S. Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma). UpToDate. ©2019. Updated 7/15/2019
36. Xeljanz (tofacitinib) [prescribing information]. New York, NY: Pfizer; December 2019.

Policy History		
#	Date	Change Description
3.9	Effective Date: 05/27/2025 P&T Date: 04/10/2025	Updated to add Avtozma and criteria requiring the member to self-administer unless clinically unable to do so
3.8	Effective Date: 02/20/2025	UM medical management system update for BCBS and BCN for Avtozma
3.7	Effective Date: 10/03/2024	Added "for the same indication" to the not to be used in combination with other biologics or targeted DMARDs criteria
3.6	Effective Date: 07/01/2024	UM medical management system update for MAPPO and BCNA for Tyenne
3.5	Effective Date: 05/01/2024	UM medical management system update for MAPPO and BCNA for Tofidence
3.4	Effective Date: 04/11/2024	Added biosimilar Tyenne to the policy
3.3	Effective Date: 03/21/2024	UM medical management system update for BCBS and BCN for Tyenne
3.2	Effective Date: 12/14/2023	Changed policy name from Actemra to Tocilizumab Products Policy due to approval of biosimilar Updated to add Tofidence, FDA approved indications criteria, and criteria to allow coverage for biosimilar products for FDA labeled indications of the innovator product
3.1	Effective Date: 10/19/2023	UM medical management system update for BCBS and BCN for Tofidence
3.0	Effective Date: 04/06/2023	Removed DMARDs from sJIA and AOSD step options, added SSc-ILD authorization and renewal criteria, and changed CRS initial authorization period to 60 days to align with PA60 legislation
2.9	Effective Date: 04/14/2022	Updated giant cell arteritis criteria and supporting information to allow use of SC or IV formulation per updated labeling
2.8	Effective Date: 12/09/2021	Removed FDA approved indications criteria
2.7	Effective Date: 04/08/2021	Updated to include criteria for new indication of SSc-ILD
2.6	Effective Date: 02/04/2021	Addition of criteria for coverage of Still's disease, including AOSD

2.5	Effective Date: 12/03/2020	Criteria updated to align management between pharmacy and medical benefit for all listed indications Updated all background information
2.4	Effective Date: 10/08/2020	Annual review of criteria was performed, no changes were made.
2.3	Effective Date: 11/07/2019	Annual review of criteria was performed, no changes were made.
2.2	Effective Date: 11/01/2018	Updated policy with new preferred product verbiage to apply to all indications
2.1	Effective Date: 08/09/2018	Updated policy with new preferred product verbiage
2.0	Effective Date: 02/08/2018	Criteria Update: GCA and CRS
1.9	Effective Date: 07/05/2017	UM medical management system update for MAPPO and BCNA for Actemra
1.8	Effective Date: 03/23/2017	New coverage criteria for biologics that treat rheumatoid conditions
1.7	Effective Date: 02/09/2017	Updated: PJIA & SJIA formatting within the coverage criteria section.
1.6	Effective Date: 07/01/2016	UM medical management system update for BCN for Actemra
1.5	Effective Date: 05/05/2016	Updated step therapy requirements: T/F of Remicade and Simponi Aria
1.4	Effective Date: 02/13/2014	Updated Actemra subcutaneous
1.3	Effective Date: 08/08/2013	Updated PJIA indication
1.2	Effective Date: 01/22/2013	UM medical management system update for BCBS for Actemra
1.1	Effective Date: 08/09/2012	Criteria Updates: Criteria, Dose. Considerations
1.0	Effective Date: 04/2010	Policy History: - Custom/Clinical Formulary: May Add - Part D: B vs D; if D then specialty tier based on pricing - Part D formulary chapter: 6D Miscellaneous Rheumatologic Agents Immunology and Hematology: - Miscellaneous Immunologic and Hematologic Agents

** The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or http://dailymed.nlm.nih.gov/dailymed/index.cfm.*